.png)
.png)
Chief Medical Officer
Entasis Therapeutics
Disclosure(s): Entasis Therapeutics: Ownership Interest, Stocks/Bonds
David Altarac, M.D., has served as the chief medical officer of Entasis Therapeutics since November 2019. From July 2015 to April 2019, Dr. Altarac was a senior vice president and head of global regulatory affairs, global drug safety and R&D quality and compliance at Shire Inc. Prior to joining Shire, Dr. Altarac was vice president, regulatory affairs at NeoStem Inc., a biopharmaceutical company developing novel, cell-based, individualized therapeutics from July 2013 to June 2015. Prior to joining NeoStem, Dr. Altarac served various roles in regulatory affairs at Merck and Company including leading the regulatory respiratory franchise, Merck’s Worldwide Product Labeling organization, and Emerging Markets regulatory affairs. Dr. Altarac holds an M.D. degree from New York Medical College, a Master of Public Administration (M.P.A.) degree from New York University, and a B.A. in Chemistry from the State University of New York at Binghamton, New York. Dr. Altarac completed his Internal Medicine residency and Infectious Diseases fellowship at Beth Israel Medical Center in New York. Dr. Altarac has held multiple academic, hospital and post graduate teaching appointments during his career and has authored/coauthored numerous scientific publications.